Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Drugs companies are working to develop new injectable drugs to treat people with severe asthma, who do not respond well to traditional inhalers.
As severe asthma is a relatively new area of healthcare, the companies are currently competing to become leaders in the field.
Despite treatment advances in recent decades, asthma is still not well controlled in up to 20% of patients on standard therapy, which consists of inhaled steroids and long-acting beta agonists that are designed to open the airways.
New antibody-based drugs work by targeting key chemicals made in the body that cause inflammation of the airways and lead to asthma symptoms. ERS President-Elect, Elisabeth Bel, said: “I’m very optimistic about the new drugs. We have participated in several trials with the new biological agents and have seen some amazing results.”
Significantly, the new drugs offer a more personalized approach to asthma care, with patients undergoing so-called “biomarker” blood tests to check if they are likely to respond to the medicines.
The EU-funded U-BIOPRED project, which ELF is a partner of, is also working towards defining the different types of severe asthma to help drug companies develop a more personalised approach to treatment.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description